The majority of human genes are alternatively spliced in a highly tissueand cell type-specific manner 1,2 . The outcome of alternative splicing is controlled by combinatorial use of multiple cis-acting RNA elements along the precursor mRNA (pre-mRNA) 3 . In addition, recruitment of regulatory splicing factors can be influenced by chromatin modifications, transcriptional regulators and the RNA polymerase II elongation rate [4] [5] [6] [7] [8] [9] [10] [11] . An example of the contribution of chromatin to tissuespecific alternative splicing is the FGFR2 gene, encoding human fibroblast growth factor receptor 2 (ref. 12). In human mesenchymal stem cells (hMSCs), FGFR2 is enriched in dimethylated (me2) and trimethylated (me3) histone H3 K36 (H3K36me2,3), which inhibits inclusion of the alternatively spliced exon IIIb 12 . This effect occurs via a chromatinsplicing adaptor system in which the chromatin-binding protein MRG15 recognizes H3K36me2,3 (ref. 13) and, through protein-protein interaction, recruits the negative splicing regulator PTB to exon IIIb 12 . In contrast, in epithelial PNT2 cells, in which exon IIIb is included, FGFR2 contains lower levels of H3K36me2,3 and is instead enriched in H3K27me3, a hallmark of Polycomb group-dependent gene silencing 12 , suggesting a nontranscriptional role of this histone modification in FGFR2 regulation. Here we sought to elucidate the role of H3K27me3 in regulation of FGFR2 splicing and to delineate how cell type-specific splicing patterns are established and maintained.
a r t i c l e s
The majority of human genes are alternatively spliced in a highly tissueand cell type-specific manner 1, 2 . The outcome of alternative splicing is controlled by combinatorial use of multiple cis-acting RNA elements along the precursor mRNA (pre-mRNA) 3 . In addition, recruitment of regulatory splicing factors can be influenced by chromatin modifications, transcriptional regulators and the RNA polymerase II elongation rate [4] [5] [6] [7] [8] [9] [10] [11] . An example of the contribution of chromatin to tissuespecific alternative splicing is the FGFR2 gene, encoding human fibroblast growth factor receptor 2 (ref. 12) . In human mesenchymal stem cells (hMSCs), FGFR2 is enriched in dimethylated (me2) and trimethylated (me3) histone H3 K36 (H3K36me2,3), which inhibits inclusion of the alternatively spliced exon IIIb 12 . This effect occurs via a chromatinsplicing adaptor system in which the chromatin-binding protein MRG15 recognizes H3K36me2,3 (ref. 13 ) and, through protein-protein interaction, recruits the negative splicing regulator PTB to exon IIIb 12 . In contrast, in epithelial PNT2 cells, in which exon IIIb is included, FGFR2 contains lower levels of H3K36me2,3 and is instead enriched in H3K27me3, a hallmark of Polycomb group-dependent gene silencing 12 , suggesting a nontranscriptional role of this histone modification in FGFR2 regulation. Here we sought to elucidate the role of H3K27me3 in regulation of FGFR2 splicing and to delineate how cell type-specific splicing patterns are established and maintained.
RESULTS

Polycomb and KDM2a modulate FGFR2 alternative splicing
To delineate the mechanism of epithelial-specific regulation of FGFR2 splicing by H3K27me3, we first probed for the enrichment of H3K27-associated chromatin proteins by chromatin immunoprecipitation (ChIP). Consistently with elevated levels of H3K27me3 and H3K9me3 along the FGFR2 locus in PNT2 cells ( Supplementary Fig. 1a-g ), EZH2 and SUZ12 of the H3K27 methyltransferase Polycomb repressive complex 2 (PRC2), together with the H3K27me3-binding protein CBX8 and the H3K9me3-binding protein HP1γ, were enriched along FGFR2 in PNT2 cells (Fig. 1a-h and Supplementary Fig. 1r ). In addition, the H3K36 demethylase KDM2a, which coimmunoprecipitated with SUZ12 but did not bind to CBX8 (Supplementary Fig. 1s ), accumulated over FGFR2 in PNT2 cells in which H3K36me2,3 levels were low (Fig. 1i,j and Supplementary Fig. 1d-i) . In contrast, several other members of the Polycomb PRC1 (Bmi1 and Ring1B) and PRC1-like BCOR complexes (BCOR, HP1α and the H3K36 demethylase KDM2b) were not differentially enriched along FGFR2 in PNT2 cells compared to hMSCs (Fig. 1k,l and Supplementary Fig. 1j-r) . We conclude that several Polycomb-related proteins and KDM2a are differentially recruited along FGFR2 in a cell type-specific manner, and this differential recruitment correlates with FGFR2 splicing outcome.
Given their accumulation across FGFR2 and their correlation with splicing outcome, we tested whether the chromatin regulators EZH2 and KDM2a were functionally relevant for splicing. Induced expression of EZH2 (alone or in combination with PHF1, an enhancer of EZH2 trimethylase activity 14 ) or expression of KDM2a increased exon IIIb inclusion in hMSCs by ~2.2-fold but did not affect exon IIIc usage ( Fig. 1m-v and Supplementary Figs. 2 and 3) . Conversely, downregulation of KDM2a, and to a lesser extent EZH1 and EZH2, moderately reduced inclusion of exon IIIb in favor of exon IIIc usage ( Supplementary Fig. 4 ). The effect on FGFR2 splicing was not due to changes in expression of FGFR2-regulatory splicing factors ( Supplementary Figs. 2-4 ) and was gene specific because splicing of other PTB-dependent genes (PKM2 (official symbol PKM) and TPM2) and alternatively spliced control genes (CD44 and HMGA1) were not altered (Fig. 1p,q 
,u,v and Supplementary Figs. 2-4).
EZH2 recruits KDM2a to FGFR2 and favors exon IIIb inclusion
In order to uncover the molecular mechanisms by which EZH2 and KDM2a bring about changes in FGFR2 splicing, we analyzed their downstream effects in hMSC cells. As expected, expression of EZH2 and PHF1 in hMSCs increased levels of EZH2 and H3K27me3 along FGFR2 but not CD44 or HMGA1 alternatively spliced control genes ( Fig. 2a-d and Supplementary Fig. 5a,b) . Consistently with SUZ12-mediated interaction of KDM2a with PRC2 ( Supplementary Fig. 1s ), EZH2 also induced recruitment of KDM2a along the FGFR2 locus to an extent similar to that of the observed increase in H3K27me3 levels (Fig. 2e,f and Supplementary Figs. 2p-r and 5c,d ). In agreement with this result, H3K36me2 and H3K36me3 levels were reduced along FGFR2, but not along the control genes CD44 or HMGA1, upon expression of EZH2 and PHF1 (Fig. 2g,h and Supplementary Fig. 5e,f) . In turn, KDM2a expression in hMSCs reduced H3K36me2 levels along FGFR2, as did expression of EZH2 and PHF1, and it also reduced recruitment of the H3K36me2,3-binding protein MRG15, which has previously been shown to act as an adaptor between chromatin and PTB, the repressor of FGFR2 exon IIIb splicing 12 (Fig. 2i-l and Supplementary Figs. 3p,q and 5g-j) . To directly test whether H3K27me3 and EZH2 exert their effect on FGFR2 alternative splicing via KDM2a, we expressed EZH2 in hMSCs after knockdown of KDM2a by RNA interference (RNAi). EZH2 failed to induce exon IIIb inclusion in the absence of KDM2a (Fig. 2m-s) , thus suggesting that PRC2's effect on splicing was dependent on KDM2a. These results indicate that EZH2 promotes exon IIIb inclusion by maintaining low H3K36me2,3 levels via recruitment of KDM2a, which impairs binding of the exon IIIb-inhibitory chromatinsplicing adaptor complex MRG15-PTB. The antagonistic effect of H3K36me3 and H3K27me3 on FGFR2 splicing points to cross-talk between these histone modifications, thus suggesting a combinatorial role of histone marks on alternative-splicing regulation 15 .
An antisense FGFR2 lncRNA is expressed when exon IIIb is included A key question in chromatin-mediated splicing control is how the regulatory chromatin domains are established and maintained 15 . Recent observations have pointed to a prominent role of lncRNAs in establishing chromatin domains 16 . These lncRNAs act via recruitment of chromatin-modifying complexes, including Polycomb-related proteins, to specific genomic locations [16] [17] [18] [19] [20] [21] [22] . ChIP mapping of histone modifications around the FGFR2 gene locus in epithelial PNT2 cells revealed several features of a transcriptionally active promoter, including enrichment of H3K4me3 and a peak of the transcription initiationcompetent phospho-Ser5 RNA polymerase II along the alternatively spliced FGFR2 IIIb-IIIc intragenic region ( Supplementary  Fig. 6a-c) . 5′ and 3′ rapid amplification of cDNA ends (RACE) in MCF7 and PNT2 epithelial cells identified an antisense transcript of 875 nt in length and starting 282 bp upstream of exon IIIc (Fig. 3a , a r t i c l e s npg a r t i c l e s Supplementary Fig. 6d ). Northern blotting with three consecutive probes complementary to the antisense FGFR2 transcript (asFGFR2), combined with a sense intronic probe and two antisense probes downstream of the putative antisense lncRNA to exclude nonspecific or artifactual detection of sense-strand FGFR2 transcripts, confirmed the existence of the antisense lncRNA in MCF7 and PNT2 cells, in which FGFR2 exon IIIb is included (Fig. 3a,b and Supplementary Fig. 6e ). This lncRNA was absent in hMSC, myofibroblast PRC30 and skin fibroblast CRL cells, which do not include exon IIIb (Fig. 3c and Supplementary Fig. 6f ). We confirmed the presence and cell specificity of asFGFR2 by strand-specific quantitative reverse-transcription PCR (qRT-PCR) in MCF7, PNT2 and hMSC cells (Supplementary Fig. 6g ). Northern blotting with exonic and intronic probes indicated that the antisense lncRNA is not spliced, and 3′ RACE demonstrated that asFGFR2 is not polyadenylated ( Supplementary  Fig. 6d,e) . As expected for a splicing regulator, we found asFGFR2 predominantly in the nuclear fraction by strand-specific qRT-PCR (Supplementary Fig. 6h ). Finally, we identified three mouse ESTs with more than 89% similarity to asFGFR2; this suggests that asFGFR2 is evolutionary conserved (Supplementary Fig. 6d ).
asFGFR2 lncRNA modulates FGFR2 alternative splicing To test whether asFGFR2 regulates exon IIIb-IIIc splicing, we downregulated it with locked nucleic acid (LNA) antisense oligonucleotides targeting antisense exon IIIc and asFGFR2 5′ untranslated regions (UTRs). Knockdown of asFGFR2 to background levels reduced exon IIIb inclusion more than 40% and almost doubled exon IIIc inclusion in PNT2 cells without affecting CD44 splicing, FGFR2 transcript levels or expression of several well-established regulators of FGFR2 splicing (Fig. 3d-i and Supplementary Fig. 7a-k) . Importantly, the use of strandspecific short interfering RNAs (siRNAs) against antisense exon IIIc gave similar results, whereas siRNAs against antisense IIIb did not affect exon IIIb-inclusion levels, thus supporting a specific role for asFGFR2 in exon IIIb inclusion ( Supplementary Fig. 7l -o and data not shown). Conversely, ectopic expression of asFGFR2 in hMSCs induced inclusion of exon IIIb in favor of exon IIIc by approximately three-fold ( Fig. 3j-n and Supplementary Fig. 7p-z) , which was similar to the splicing change observed upon downregulation of the splicing repressor PTB (Supplementary Fig. 6m-n) . It is important to note that, unlike the splicing-activator protein ESRP1 (ref. 23 ), asFGFR2 does not activate exon IIIb inclusion but inhibits its repression by interfering with PTB recruitment. We therefore did not expect a larger effect on FGFR2 splicing upon expression of asFGFR2 than that caused by the downregulation of PTB itself 24 . As a control, we expressed a GAPDH antisense transcript (asGAPDH), which had no effect on FGFR2 splicing (Fig. 3j-n and Supplementary Fig. 7p-z) . The asFGFR2 splicing effect was gene specific because exons with high sequence complementarity to FGFR2-IIIb in FGFR1 and FGFR3 were not affected ( Supplementary  Fig. 7a-f npg a r t i c l e s in asFGFR2, thus making it unlikely that the effect of asFGFR2 is due to suppression of FGFR2-regulatory factors. Finally, unlike small RNAs that have previously been reported to alter alternative splicing by inducing Argonaute recruitment 4, 25, 26 , the asFGFR2 effect was RNAi independent because downregulation of Argonautes 1 and 2 or Dicer affected neither FGFR2 splicing in PNT2 cells nor induction of exon IIIb inclusion in hMSCs upon asFGFR2 expression (Fig. 4) . We conclude that an antisense lncRNA expressed from within the FGFR2 gene modulates FGFR2 alternative splicing.
asFGFR2 modulates FGFR2 splicing by recruiting PRC2 and KDM2a
To explore the mechanisms of asFGFR2 splicing regulation, we examined the consequences of expressing asFGFR2 in hMSCs. Ectopic expression of asFGFR2 lncRNA, but not control asGAPDH, induced recruitment of the PRC2 component SUZ12, but not the PRC1 components Ring1b or KDM2b, to the FGFR2 locus (Fig. 5e,f and Supplementary Fig. 8a-h ). It also increased H3K27me3 levels along the FGFR2 alternatively spliced region (e7 to e9), by approximately two-fold, but not in downstream constitutively spliced exons (i13-e15) (Fig. 5g,h) . In contrast, downregulation of asFGFR2, which is immunoprecipitated by SUZ12 in PNT2 cells, reduced SUZ12 and H3K27me3 levels, thus supporting a role for asFGFR2 in tethering the Polycomb complex to FGFR2 (Fig. 5a-d,p) . In agreement with the observed recruitment of KDM2a to PRC2-and H3K27me3-rich chromatin, asFGFR2 expression in hMSCs also enhanced KDM2a binding along FGFR2 by approximately two-fold, and this in turn lowered H3K36me2 levels and binding of the repressive chromatin-adaptor MRG15 along the FGFR2 alternatively spliced region. Consequently, binding of the splicing regulator PTB to exon IIIb pre-mRNA was severely reduced by asFGFR2 expression, which promoted exon IIIb inclusion (Fig. 5i-o and Supplementary Fig. 8e-k) . Deletion mutants of asFGFR2 demonstrated that antisense exon IIIc (asIIIc), lacking the intronic regions, was sufficient to induce exon IIIb inclusion in hMSC cells, whereas expression of a truncated antisense exon IIIc transcript (asIIIc 1/2 ) or an antisense sequence containing FGFR2 exon IIIb, but not exon IIIc (del(IIIc)), was not sufficient (Fig. 6a-d) . These results suggest that the antisense IIIc exonic region is necessary and sufficient for the function of asFGFR2. In support of this, an antisense sequence lacking exon IIIc was unable to induce recruitment of SUZ12 to FGFR2 and failed to increase H3K27me3 levels in hMSCs (Fig. 6e-h) , thus confirming that this region drives asFGFR2-dependent recruitment of the PRC2 complex to the gene locus. Of note, expression of asFGFR2 in mesenchymal cells favored exon IIIb inclusion relative to IIIc to a greater extent than increased expression of EZH2 or KDM2a and to a similar level as inhibition of PTB itself, suggesting that asFGFR2 induces recruitment of chromatin regulators to FGFR2 more efficiently than upon global expression (Figs. 1m-v and 3j-n and Supplementary Figs. 2, 3, 6m,n and 7p-z) . These results demonstrate that asFGFR2 promotes epithelial-specific splicing of FGFR2 by creating a cell type-specific chromatin environment, along the alternatively spliced region, that is unfavorable to the recruitment and binding of the splicing repressor PTB to its specific RNA-binding sites along exon IIIb. In support of a role for asFGFR2 in maintaining the FGFR2 IIIb splicing isoform in a physiological context, asFGFR2 expression levels were severely downregulated during epithelial-to-mesenchymal transition, concomitantly with a splicing switch from FGFR2 exon IIIb to exon IIIc ( Supplementary Fig. 6i-l) .
asFGFR2 effect on FGFR2 splicing is chromatin dependent
To finally test whether asFGFR2 acts through remodeling of chromatin rather than interference ** ** ** ChIP values (mean ± s.e.m.; n = 3 independent experiments for downregulation and n = 4 for ectopic expression) are shown as the percentage of input or normalized to control H3. *P < 0.05; **P < 0. 
npg a r t i c l e s
with FGFR2 pre-mRNA, we expressed asFGFR2 in hMSCs after siRNA knockdown of KDM2a and probed FGFR2 splicing patterns. Whereas asFGFR2 induced exon IIIb inclusion in the presence of KDM2a, it had no effect on FGFR2 splicing in the absence of KDM2a, thus suggesting a chromatin-dependent function of the lncRNA (Fig. 6i-m and Supplementary Fig. 8m ). Furthermore, asFGFR2 lacked sequence homology with exon IIIb or its PTB-binding sites, and expression of only antisense IIIc exonic sequence, without intronic regions, affected FGFR2 splicing, thus ruling out potential interference of asFGFR2 with PTB binding or recruitment of the spliceosome to the FGFR2 pre-mRNA. In addition, RNase A digestion failed to protect the asFGFR2 sequence, and chromatin pulldown of a biotinylated asFGFR2 RNA sequence showed that upon overexpression of the lncRNA, asFGFR2 was targeted to the FGFR2 locus precisely around the IIIc region ( Fig. 6n and Supplementary Fig. 8l ). When taken together, these observations support a mechanism by which the expression of asFGFR2 lncRNA in epithelial cells creates, via direct or indirect recruitment of the Polycomb complex PRC2 and KDM2a to the FGFR2 locus, a splicing-specific chromatin signature that favors exon IIIb inclusion by interfering with recruitment of inhibitory splicing regulators, such as PTB (Fig. 6o) .
DISCUSSION
Here we report regulation of alternative splicing by a lncRNA. Our data suggest a mechanism in which an antisense lncRNA establishes and maintains cell type-specific splicing patterns via epigenetic mechanisms involving histone modifications and the Polycomb complex. Our finding that H3K36me2,3 and H3K27me3 have antagonistic effects on FGFR2 splicing outcome and that the H3K36 demethylase KDM2a is recruited to H3K27me3-rich chromatin suggests cross-talk between histone modifications rather than independent action of these epigenetic marks in the regulation of alternative splicing 15 . The lncRNA generated from within FGFR2 is necessary to maintain the epithelial-specific splicing pattern of FGFR2 in PNT2 cells, and, upon experimental overexpression, it is sufficient to establish an epithelial-specific chromatin signature that promotes exon IIIb inclusion in mesenchymal cells. The asFGFR2 effect on splicing is comparable in size to downregulation of the splicing repressor PTB or downregulation of the splicing regulator IWS1, which was recently shown to induce cell migration and invasiveness in lung tumor cells via modulation of FGFR2 IIIb-IIIc splicing through recruitment to FGFR2 of the H3K36 methyltransferase SETD2 and the chromatinadaptor complex MRG15-PTB 11 . Even though antisense lncRNAs npg generally act in cis by staying attached to their transcriptional units and locally recruit chromatin-remodeling complexes 27 , we found that exogenously expressed asFGFR2, albeit at considerably higher levels than its endogenous counterpart, can also affect its target locus in trans, by targeting the FGFR2 locus precisely around the IIIc region, possibly by forming RNA-DNA heteroduplexes via sequence complementarity 28 . We suggest that chromatin-based regulatory mechanisms of alternative splicing, such as the one described here, act in concert with other known alternative-splicing mechanisms, including elongation-dependent splicing-factor recruitment and cis-acting RNA elements, to optimize and fine-tune cell type-and tissue-specific alternative-splicing patterns.
We have here used the well-characterized FGFR2 gene as a model system to study the role of an antisense lncRNA in cell-specific alternative splicing. The identification of highly homologous asFGFR2 lncRNAs in mice suggests an evolutionary conservation of this mechanism of splicing regulation. Furthermore, computational analysis of expression data from 176 human lymphoblastoid cell lines has shown that ~75% of the identified areas of senseantisense gene overlap are in alternatively spliced regions 29 , and we have identified 29 antisense transcripts that are expressed within PTB-dependent alternatively spliced genes, among which 55% are also MRG15 dependent, thus suggesting that lncRNAs may have a more universal role in chromatin-dependent alternative-splicing control. Given the highly tissue-specific and developmentally regulated expression of lncRNAs 30 , we propose antisense lncRNAs as a new mechanism in determining cell-and tissue-specific alternative-splicing patterns.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Cell lines and plasmids. Human normal prostate epithelial PNT2 cells (Sigma) and immortalized human mesenchymal hMSC stem cells 31 were grown at 37 °C, 5% CO 2 in RPMI (Invitrogen) and DMEM (Invitrogen), respectively, both supplemented with 10% fetal bovine serum. Human mammary epithelial MCF10a-Snail-ER cells, which stably express the epithelial repressor Snail1 fused to the estrogen receptor, were kindly provided by D. Haber (Massachusetts General Hospital) and cultured as previously described 32 . Briefly, to induce the epithelial-to-mesenchymal transition, MCF10-Snail-ER cells were treated with 100 nM tamoxifen (Sigma) for 6 d. Importantly, parental MCF10a cells did not show any differences in cell morphology or transcriptional and splicing patterns upon the same treatment. All cell lines were regularly tested for mycoplasma. Plasmids were nucleoporated in PNT2 and hMSC cells according to the manufacturer's recommendations. Briefly, 3-5 µg of endo-free plasmid prepared by Maxi prep (Qiagen) was electroporated with an Amaxa nucleoporator into 1 × 10 6 cells resuspended in 100 µl of either solution V (T30 program) for PNT2 cells or solution hMSC (C17 program) for hMSC cells. 55%-65% of cells typically survived, thus allowing for ~60%-65% transfection efficiency. For transfection of higher numbers of cells, 20 µg of plasmid was electroporated (220 V, 5 × 1-ms pulses) into 4 × 10 6 hMSCs in 100 µl of DMEM. After 72 h in culture, transfected cells were used for experimentation. pCMV-FlaghKDM2a was provided by R. Klose (University of Oxford); pEBB-Flag-hEZH2 was provided by C.S. Duckett (University of Michigan); and pCMV4-Flag-hPHF1 was provided by D. Reinberg (NYU Langone Medical Center). pCDNA3.1 (+) (Clontech) was used as a negative control (mock). Human antisense FGFR2 (asFGFR2) was amplified by PCR, on the basis of 5′-and 3′-RACE results, and cloned in the mammalian expression vector pCDNA3.1 (+). It is 875 nt long, starts right before antisense exon IIIc and ends in intron i8 in the antisense direction. asFGFR2 mutants expressing different exons from FGFR2 in the antisense direction were synthesized by GenScript and subcloned in pCDNA3.1 (+). As a control, 300 bp of human GAPDH 3′ UTR were cloned in an antisense direction in pCDNA3.1 (+) (pCDNA3-asGAPDH).
Quantitative RT-PCR and strand-specific RT-PCR. Total RNA was extracted with the RNeasy Plus Mini kit (Qiagen), and 500 ng of RNA was retrotranscribed (RT) by random priming into cDNA with a High Capacity cDNA RT kit (Applied Biosystems), according to the manufacturers' instructions. Quantification of the amount of cDNA was done with SsoFast EvaGreen Supermix for real-time qPCR (CFX96, Bio-Rad) with oligonucleotide sequences that specifically recognize FGFR2-IIIb, FGFR2-IIIc, TPM2-e6, TPM2-e7, PKM2-e9 and PKM2-e10 splicing variants, and FGFR2-e4, FGFR2-e14 and FGFR2-e15 constitutive exons. CD44 exon variant v6 and HMGA1 exon e2 were used as controls for PTB-independent alternative-splicing events. The gene encoding cyclophilin A was used as a housekeeping control. The percentage of exon inclusion was obtained by division of the expression levels of the alternatively spliced exon by the total expression levels of the corresponding transcript by looking at constitutive exons.
The lncRNA asFGFR2 was detected by strand-specific RT. Gene-specific primers (GSPs) that bind to antisense exons IIIc were used to retrotranscribe asFGFR2 with a Transcriptor First-Strand cDNA Synthesis kit (Roche) at 55 °C, according to the manufacturer's instructions. The asFGFR2 was detected by qRT-PCR by amplification of its 5′-UTR cDNA fragment, corresponding to the sequence identified by 5′ RACE and antisense exon IIIc. To test the strand specificity of the RT, we amplified FGFR2 exons e4 and e5 (referred to as Ctl) that are not present in the antisense cDNA. An RT with no primers was used as a negative control, and results were represented as the fold increase with respect to the RT with no primers. The oligonucleotide sequences used are listed in Supplementary Table 1. RNAi knockdown. Downregulation of EZH1, EZH2, KDM2a, SUZ12, Argonaute 1, Argonaute 2, Dicer and PTB was performed with siGENOME SMARTpool siRNA oligonucleotides (knockdown efficiencies in Supplementary Data Set 2). Downregulation of asFGFR2 was performed with either custom ON-TARGET plus strand-specific siRNA oligonucleotides against antisense exons IIIc or IIIb, to demonstrate specificity (Dharmacon), and strand-specific LNA GapmeRs antisense oligonucleotides against the 5′-UTR and exon IIIc regions of asFGFR2 (Exiqon). siGENOME nontargeting siRNA was used as a negative control. A maximum of 50 to 100 nM total of siRNA oligos was delivered to cells for 72 h with the transfection reagent DharmaFECT 1 (Dharmacon), according to the manufacturer's instructions. For cotransfection of plasmids and siRNA oligos, 1 µg of plasmid together with 50 nM total of siRNA was delivered to the cells with DharmaFECT Duo reagent (Dharmacon). Knockdown efficiency was typically 60%-75%, as assessed by qRT-PCR.
Chromatin immunoprecipitation (ChIP).
ChIP was performed as previously described 12 , with approximately 2 × 10 6 cells per sample. Samples were crosslinked for 10-15 min in 1% formaldehyde at room temperature, nuclear extracts were collected and the purified chromatin was sonicated in an ultrasonic bath Additional validation information is available on the respective manufacturers' websites. Beads were washed and eluted in 1% SDS and 100 mM NaHCO 3 buffer for 15 min at 65 °C, and cross-linking was reversed for 6 h. Chromatin was precipitated with ethanol overnight, treated with proteinase K and purified with QiaQuick PCR-purification columns (Qiagen), according to the manufacturer's instructions. Immunoprecipitated DNA (1.5 µl) and serial dilutions of 10% input DNA (1:2, 1:10, 1:50 and 1:250) were analyzed by SYBR-Green real-time qPCR. The percentage input between samples was normalized with rabbit anti-histone H3, when indicated, for better comparison between cell types and experimental conditions. The oligonucleotide sequences used are listed in Supplementary Table 1. Rapid amplification of cDNA ends (RACE). 5′RACE. 10 µg of MCF7 and PNT2 total RNA, extracted with TRIzol (Invitrogen), was subjected to 5′ RACE with a First Choice RLM-RACE kit (Ambion), according to the manufacturer's instructions. The obtained cDNA was subjected to nested touchdown PCR with strand-specific primers designed within FGFR2 intron 8 (R_5.1) and inner exon IIIc (R_5.2). The resulting PCR product was purified with a GeneJET PCR Purification kit (Fermentas) and cloned into pGEM-T easy vector (Promega) for sequencing. Sequences from different clones were aligned to human genome build 19 (hg19) with the BLAT search engine. A negative control without tobacco acid pyrophosphatase (TAP) treatment was performed. The oligonucleotide sequences used are listed in Supplementary Table 1. 3′RACE. Nuclear RNA from MCF7 and PNT2 cells was extracted with a Cytoplasmic and Nuclear RNA Purification kit (Norgen). Nuclear RNA was in vitro poly(A)-tailed with a poly(A) polymerase (Ambion), according to the manufacturer's protocol. The polyadenylated RNA was ethanol precipitated and treated with a Turbo DNA-free kit (Ambion). 2 µg of poly(A) RNA was reverse transcribed with a RevertAid First Strand cDNA Synthesis kit (Thermo) and RTpoly(T) primer. The obtained cDNA was subjected to nested touchdown PCR with two pairs of gene-specific primers and the poly(T) adaptors. The resulting PCR products were purified with a GeneJET PCR Purification Kit (Fermentas) and cloned into the pGEM-T easy vector (Promega) for sequencing. Sequences from different clones were aligned to human genome build 19 (hg19) with the BLAT search engine. The oligonucleotide sequences used are listed in Supplementary  Table 1 , and the full asFGFR2 sequence obtained is in Supplementary Table 2 .
Northern blotting. Northern blotting was performed with the Ambion NorthernMax kit, as recommended by the manufacturer. Briefly, 25 µg of npg DNase I-treated total RNA extracted with TRIzol (Invitrogen) was loaded in a 1% denaturing formaldehyde-agarose gel for separation of the RNA transcripts by electrophoresis. RNA was transferred onto an Ambion BrightStarPlus membrane by capillarity for less than 2 h at room temperature and was immediately UV cross-linked to reduce RNA degradation. The membrane was prehybridized for 30-60 min at 68 °C in hybridization buffer, while RNA probes were labeled with radioactive [ 32 P]UTP. 10 6 c.p.m./mL of columnpurified labeled riboprobe was added to the membrane for overnight hybridization at 68 °C in a rotating oven. After several washes at 68 °C and room temperature, the blot was exposed to film for autoradiography. RNA probes complementary to the FGFR2 antisense exon IIIc (asIIIc), antisense intron i8 (asI8-IIIc), antisense exon IIIb (asIIIb-I8), antisense e7 (asE7), the region detected by 5′ RACE (5′ UTR), sense exon 7 (E7), sense intron 8 (senseI8) and GAPDH 3′ UTR as control were in vitro transcribed with a MAXIscript kit (Ambion). The size of the lncRNA was estimated with a nonradiolabeled RNA ladder (Ambion) run on the same agarose gel as the RNAs for transfer, detected with BrET and then marked on the blot by taking the wells as a reference.
Coimmunoprecipitation and western blotting. As previously described 12 , crosslinked chromatin was isolated and sonicated for immunoprecipitation with 60 µl of magnetic beads (anti-IgG Dynabeads M-280 Invitrogen) coated with either rabbit anti-CBX8 (provided by K. Helin (University of Copenhagen, Denmark)), rabbit anti-SUZ12 (Cell Signaling 3737) or no antibody, as a negative control, in 750 µl sonication buffer overnight at 4 °C. Immune complexes were washed and eluted in 20 µl SDS sample buffer for 15 min at 95 °C. Proteins were separated on 10% SDS-PAGE and transferred onto nitrocellulose membrane. After 1 h blocking, the membrane was incubated with rabbit anti-KDM2a (provided by R. Klose (University of Oxford)) and rabbit anti-CBX8 or rabbit anti-SUZ12 as positive controls of the immunoprecipitation. Horseradish peroxidase-conjugated secondary antibodies were detected with the ECL Substrate system (Pierce).
RNA immunoprecipitation (RNA-IP).
As previously described 12 , approximately 5 × 10 6 cells per IP were cross-linked with 1% formaldehyde. Nuclear extracts were collected and sonicated for immunoprecipitation with 40 µl of magnetic beads (anti-IgG Dynabeads M-280 Invitrogen) coated with rabbit anti-PTB (provided by M. Garcia-Blanco (Duke University)), rabbit anti-SUZ12 (Cell Signaling 3737) or IgG as a negative control. Antibody specificity is shown in Supplementary Data Set 2. After washes in high-salt RIPA buffer, beads were eluted, and the cross-linking was reversed for 1 h at 70 °C in 200 µl of elution buffer (50 mM Tris-HCl, pH 7.0, 5 mM EDTA, 10 mM dithiothreitol (DTT) and 1% SDS). RNA was extracted with TRIzol (Invitrogen), DNase I treated and retrotranscribed with either random primers or gene-specific primers to detect asFGFR2. Immunoprecipitated RNA and serial dilutions of the 10% input RNA were analyzed by SYBR-Green real-time qPCR. Results were normalized to noprimer RT and IgG RNA-IP. We used the same exon IIIb oligonucleotide sequence as in the ChIP assay and asFGFR2-5UTR as in the strand-specific RT-PCR, to detect FGFR2 pre-mRNA and asFGFR2 cDNA, respectively. All buffers were sterile, RNase free and supplemented with 100 U/ml of RNase inhibitor (RNasin, Promega) and 1× Protease Inhibitor Cocktail Set III (Calbiochem). recover a percentage of exact complementary sequence match between the two sequences, measured as the percentage of bases from the antisense Ensembl gene with exact complementarity with the alternative event. We selected the events that showed a percentage higher than 40%.
To increase the data set of antisense transcripts, we added the RNAs that were identified in Zhao et al. 19 to directly interact with PRC2 by RIP-seq of EZH2 in mouse ESCs. Locations of PRC2-interacting RNAs in the NCBI37/mm9 mouse assembly were converted with the UCSC liftover tool (http://genome.ucsc.edu/ cgi-bin/hgLiftOver/) to mm10/GRCm38 assembly coordinates and then to human hg19/GRCh37. We recovered the PRC2-interacting RNA sequences in hg19, and we intersected them with PTB-dependent-event genomic regions with fjoin 34 . We selected the events that showed overlap with PRC2-interacting RNAs from the opposite strand to the parent gene. As a second approximation, we extracted the PRC2-interacting RNA sequences of the liftover to hg19, and we calculated the percentage of exact complementary sequence match between the alternativesplicing event and the RIP-seq sequence, as explained before. Combining all these strategies, we found that 5.6% of PTB-dependent events overlap with an antisense transcript, among which 55% were also MRG15 dependent.
Statistical analysis.
All values represent means ± s.e.m. of three to eight biological replicates and follow a normal distribution. Statistical significance of the differences between tissues was estimated with the two-tailed paired Student's t test comparing either the two cell types or relative to control.
